Article
SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells.
Frontiers in bioscience (Landmark edition) - 18 Dec 2025
Kou Yu-Ling, Liu Yu-Jie, Hsu Tzu-Chi, Wu Kuan-Yo, Chen Sih-Tong, Chen Jing-Yan, Lin Kuan-Yu, Wang Hsiao-Hsuan, Cheng Yi-Ting, Chen Chia-Chi, Cai Bi-He
Abstract excerpt
BACKGROUND: TP53 gene mutations are common in breast cancer and are linked to chemoresistance. p63, a p53 family member, can induce apoptosis independently of p53, representing a potential therapeutic target in TP53-mutant tumors. This study evaluated the synergistic effects of SB431542, a TGF-β type I receptor inhibitor, and doxorubicin in TP53-mutant breast cancer cells. METHODS: Isoform-specific RT-PCR was...
Topics
Join the communities discussing this publication.